Return to the home page. top banner right
top banner bottom
Click to search.
members
Login:
Password:
Click to login
Click for Log In Help
Click to Join the Society
 
 
 
 
Click for the Heart Rhythm Foundation
Click for the IBHRE (formerly NASPExAM)
Click for Professional Education
 
 
 
 
 
 
 
 
Click for Health Policy
Click for Clinical Guidance
Click for Research
Click for News & Information
Click for Scientific Sessions
Click for the HRS Calendar
Click for the HeartRhythm Journal
Click for the HRS Store
Click to Find a Specialist
Click for Patient Information
Click for About HRS
Click for Membership
Click for Career Center
Click for the AF 360° Resource Center
Click for the SCA 360° Resource Center
titlelines DIAMOND-MI Clinical Trial
content_line

Title of Trial
DIAMOND-MI

Date and citation of primary publication(s) or References
Lancet 2000;356:2052-2058.

Purpose of the Trial
To investigate whether long-term treatment with dofetilide affects mortality and morbidity in survivors of myocardial infarctions with left ventricular dysfunction.

Study Category
Ventricular arrhythmias/Sudden Death

Patient Population
Patients with recent myocardial infarction and left ventricular dysfunction

Inclusion Criteria

  • Age > 18 years
  • Myocardial infarction within 7 days
  • Left ventricular ejection fraction < 35%
  • Provide written informed consent

Exclusion Criteria

  • Women of childbearing potential not on contraceptives
  • Myocadial infarction within 7 days
  • Heart rate < 50 beats/ minute when awake
  • Sinoatrial block or second- or third-degree atrioventricular block not treated with a pacemaker
  • History of drug-induced proarrhythmia
  • Corrected QT interval that exceeded 460 ms (500 ms in cases of bundle-branch block), or diastolic or systolic blood pressures >115 or <80 mm Hg
  • Patients also were excluded who were likely to die from other causes during the study
  • Serum potassium levels of <3.6 mEq/L (<3.6 mmol/L) or >5.5 mEq/L (>5.5 mmol/L)
  • Treatment with class I or III antiarrhythmic drugs or had participated in experimental drug studies in the previous 3 months
  • Creatinine clearance rates of <20 mL/min
  • Serious liver dysfunction, acute myocarditis, planned cardiac surgery or angioplasty, aortic stenosis, cardiac surgery within the prior 4 weeks, or the presence of an implantable defibrillator.

Study Design
Randomized, double-blind, placebo-controlled, multicenter study

Primary Endpoint
Death from any cause

Secondary Endpoints

  • Cardiac death
  • Arrhythmic death
  • Cardiac death or successful resuscitation after cardiac arrest
  • Worsening heart failure
  • Reinfarction
  • Arrhythmia requiring treatment and withdrawal of the study drug

Baseline Characteristics
Patient number: 1,510
Mean Age: 69 years
Gender: % female; 26% females
Other characteristics: 7% of patients enrolled had atrial fibrillation at randomization

Years to Follow-up

Median follow-up was 456 days

Results
No significant differences were found between the dofetilide and placebo groups in all-cause mortality (31% versus 32%), cardiac mortality (26% versus 28%), or total arrhythmic deaths (17% versus 18%). Atrial fibrillation or flutter was present in 8% of the patients at study entry. In these patients, dofetilide was significantly better than placebo at restoring sinus rhythm (25 of 59 versus 7 of 56; p=0.002). There were seven cases of torsade de pointes ventricular tachycardia, all in the dofetilide group.

Sponsors
Pfizer Central Research

Trial Status: Completed

Review written by Samir Saba, MD

Click to Email Page. Click to Print Page.
Click to Contact Us.Click for the Site Map.
© Heart Rhythm Society | 1400 K St. NW, Suite 500 | Washington DC 20005 | (202) 464-3400 | Fax: (202) 464-3401 | Privacy Policy